IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences industry. With a market cap of $38.4 billion, IQVIA is considered a large-cap stock. The company’s stock prices have risen 23.1% in the past three months, outperforming the S&P 500 Index. IQVIA reported better-than-expected Q3 results, with a 5.2% year-over-year growth in revenue and a 5.6% increase in adjusted EPS. Analysts give IQVIA a “Strong Buy” rating with a mean price target of $244.10, suggesting a 7.4% upside potential from current levels.

Read more at Barchart: Is IQVIA Holdings Stock Outperforming the S&P 500?